Research output per year
Research output per year
Personal profile
External positions
Advisory Committee, Jansen Pharmacuticals
2013 → …
vice chair Scientific Review Commitee Netherlands Leprosy Relief
2011 → 2019
Advisory Board, antifungals, Pfizer
2010 → …
Technical Advisory Group Buruli ulcer WHO
2009 → …
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Personalized Tuberculosis Care for Drug-Resistant Tuberculosis
de Reus, Y. & van der Werf, T. S., 1-Apr-2023, Tuberculosis: Integrated Studies for a Complex Disease. Rezaei, N. (ed.). Springer Nature, Vol. 11. (Integrated Science; vol. 11).Research output: Chapter in Book/Report/Conference proceeding › Chapter › Professional
-
Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial
Voriconazole ZonMw Study Group, Veringa, A., Brüggemann, R. J., Span, L. F. R., Biemond, B. J., de Boer, M. G. J., van den Heuvel, E. R., Klein, S. K., Kraemer, D., Minnema, M. C., Prakken, N. H. J., Rijnders, B. J. A., Swen, J. J., Verweij, P. E., Wondergem, M. J., Ypma, P. F., Blijlevens, N., Kosterink, J. G. W., van der Werf, T. S. & Alffenaar, J. W. C., Feb-2023, In: International journal of antimicrobial agents. 61, 2, 9 p., 106711.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile2 Citations (Scopus)12 Downloads (Pure) -
Voriconazole exposure is influenced by inflammation: A population pharmacokinetic model
Abraham van den Born, D., Märtson, A-G., Veringa, A., Punt, N. C., van der Werf, T. S., Alffenaar, J-W. C., Sturkenboom, M. G. G. & Touw, D. J., Apr-2023, In: International journal of antimicrobial agents. 61, 7 p., 106750.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Citation (Scopus)7 Downloads (Pure) -
Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients
Vogensen, V. B., Bolhuis, M. S., Sturkenboom, M. G. G., van der Werf, T. S., de Lange, W. C. M., Anthony, R. M., van Soolingen, D., Alffenaar, J-W., Kerstjens, H. A. M. & Akkerman, O. W., 15-Feb-2022, In: Antimicrobial Agents and Chemotherapy. 66, 2, 8 p., e01829-21.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile2 Citations (Scopus)112 Downloads (Pure) -
Clinical standards for drug-susceptible TB: putting patients first
VAN DER WERF, T. S. & GROBUSCH, M. P., 1-Jul-2022, In: International Journal of Tuberculosis and Lung Disease. 26, 7, p. 584-586 3 p.Research output: Contribution to journal › Editorial › Academic › peer-review
Open AccessFile18 Downloads (Pure)